Sintilimab after chemoradiation for older adults with esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether the immunotherapy drug Sintilimab can help prevent esophageal cancer from returning after standard chemotherapy and radiation. It is for patients aged 70-85 who cannot have or choose not to have surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 70 and 85 years old.
- You have been diagnosed with esophageal squamous cell carcinoma that has spread to nearby lymph nodes but not to distant organs.
- You have just completed a specific type of chemoradiation (radiation plus the chemotherapy drug S-1).
- Your cancer did not grow during chemoradiation (it shrank or stayed the same).
- You are generally well enough to care for yourself (ECOG score 0 or 1).
- Your lungs, kidneys, liver, and blood counts are working well enough based on standard tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining chemoradiation with the immunotherapy drug iparomlimab for adults aged 70 and older with advanced esophageal cancer. The goal is to see if adding immunotherapy after standard chemoradiation improves outcomes.
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy or radiation for older adults with advanced or recurrent esophageal cancer. The goal is to see if this combination is safe and effective in treating the cancer and possibly slowing its growth.
This trial tests whether adding the immunotherapy drug sintilimab to standard chemoradiotherapy can help people aged 75 or older with locally advanced stomach cancer. It aims to shrink tumors and improve outcomes.
This trial is testing whether giving a combination of an immunotherapy drug (sintilimab) with chemotherapy, followed by radiation plus more chemotherapy (concurrent chemoradiotherapy), can help people with advanced esophageal cancer that cannot be removed surgically. The goal is to see if this approach shrinks the tumor and improves outcomes.
This trial tests a combination of an immunotherapy drug (sintilimab) and chemotherapy given before and after surgery for esophageal squamous cell carcinoma. The goal is to see if this approach can improve outcomes for patients with resectable tumors in the middle or lower esophagus.
This trial tests whether giving the immunotherapy drug Sintilimab after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes and who have already had their tumor removed.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.